Free Trial
→ Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (From Banyan Hill Publishing) (Ad)tc pixel Free REVB Stock Alerts

Revelation Biosciences (REVB) Competitors

Revelation Biosciences logo
$1.07 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$1.08 +0.01 (+0.84%)
As of 05/22/2026 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

REVB vs. ZIVO, QCLS, PASG, TRAW, and LGVN

Should you buy Revelation Biosciences stock or one of its competitors? MarketBeat compares Revelation Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revelation Biosciences include ZIVO Bioscience (ZIVO), Mymd Pharmaceuticals (QCLS), Passage Bio (PASG), Traws Pharma (TRAW), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry.

How does Revelation Biosciences compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

ZIVO Bioscience's return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ZIVO BioscienceN/A N/A -2,240.92%
Revelation Biosciences N/A -107.65%-87.98%

ZIVO Bioscience has higher revenue and earnings than Revelation Biosciences. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIVO Bioscience$15.85K1,075.20-$7.78M-$1.71N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, ZIVO Bioscience's average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company Overall Sentiment
ZIVO Bioscience Neutral
Revelation Biosciences Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

ZIVO Bioscience has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

Summary

ZIVO Bioscience beats Revelation Biosciences on 7 of the 10 factors compared between the two stocks.

How does Revelation Biosciences compare to Mymd Pharmaceuticals?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Revelation Biosciences (NASDAQ:REVB) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mymd PharmaceuticalsN/AN/A-$11.63M-$20.69N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

In the previous week, Mymd Pharmaceuticals had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for Mymd Pharmaceuticals and 0 mentions for Revelation Biosciences. Mymd Pharmaceuticals' average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company Overall Sentiment
Mymd Pharmaceuticals Neutral
Revelation Biosciences Neutral

Mymd Pharmaceuticals has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market.

Mymd Pharmaceuticals' return on equity of -76.40% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Mymd PharmaceuticalsN/A -76.40% -35.10%
Revelation Biosciences N/A -107.65%-87.98%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mymd Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Mymd Pharmaceuticals beats Revelation Biosciences on 5 of the 8 factors compared between the two stocks.

How does Revelation Biosciences compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Passage Bio is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/A-$45.52M-$11.84N/A
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A

Passage Bio currently has a consensus target price of $13.25, indicating a potential upside of 153.83%. Given Passage Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Passage Bio is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Passage Bio
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Passage Bio had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for Passage Bio and 0 mentions for Revelation Biosciences. Passage Bio's average media sentiment score of 0.33 beat Revelation Biosciences' score of 0.00 indicating that Passage Bio is being referred to more favorably in the media.

Company Overall Sentiment
Passage Bio Neutral
Revelation Biosciences Neutral

Passage Bio has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Revelation Biosciences' return on equity of -107.65% beat Passage Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Passage BioN/A -150.88% -59.78%
Revelation Biosciences N/A -107.65%-87.98%

Summary

Passage Bio beats Revelation Biosciences on 10 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Traws Pharma?

Revelation Biosciences (NASDAQ:REVB) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Revelation Biosciences' return on equity of -107.65% beat Traws Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -107.65% -87.98%
Traws Pharma N/A -913.18%-133.88%

Traws Pharma has higher revenue and earnings than Revelation Biosciences. Traws Pharma is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A
Traws Pharma$2.79M5.43$9.17M-$1.69N/A

Traws Pharma has a consensus target price of $8.00, indicating a potential upside of 436.91%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Traws Pharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 14.0% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Traws Pharma had 11 more articles in the media than Revelation Biosciences. MarketBeat recorded 11 mentions for Traws Pharma and 0 mentions for Revelation Biosciences. Traws Pharma's average media sentiment score of 0.56 beat Revelation Biosciences' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Revelation Biosciences Neutral
Traws Pharma Positive

Revelation Biosciences has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Summary

Traws Pharma beats Revelation Biosciences on 11 of the 15 factors compared between the two stocks.

How does Revelation Biosciences compare to Longeveron?

Revelation Biosciences (NASDAQ:REVB) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Revelation Biosciences has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Revelation Biosciences' return on equity of -107.65% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -107.65% -87.98%
Longeveron -1,844.49%-202.41%-140.67%

Longeveron has a consensus target price of $5.50, indicating a potential upside of 570.57%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Longeveron
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Revelation Biosciences has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market.

Revelation Biosciences has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$39.48N/A
Longeveron$1.20M15.91-$22.70M-$1.13N/A

In the previous week, Longeveron had 14 more articles in the media than Revelation Biosciences. MarketBeat recorded 14 mentions for Longeveron and 0 mentions for Revelation Biosciences. Longeveron's average media sentiment score of 0.93 beat Revelation Biosciences' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.

Company Overall Sentiment
Revelation Biosciences Neutral
Longeveron Positive

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by insiders. Comparatively, 11.2% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Longeveron beats Revelation Biosciences on 8 of the 15 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REVB vs. The Competition

Export
MetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.18M$3.37B$6.46B$12.34B
Dividend YieldN/A2.26%2.76%5.28%
P/E Ratio-0.0318.7421.0025.66
Price / SalesN/A323.98558.1986.31
Price / CashN/A125.1743.4956.67
Price / Book0.327.0910.407.14
Net Income-$8.91M$24.45M$3.57B$335.98M
7 Day Performance3.88%6.38%6.40%4.11%
1 Month Performance-8.55%2.43%3.55%2.52%
1 Year Performance-96.33%62.98%34.13%35.04%

Revelation Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REVB
Revelation Biosciences
1.0913 of 5 stars		$1.07
flat		N/A-96.3%$4.18MN/AN/A10
ZIVO
ZIVO Bioscience
N/A$4.06
flat		N/AN/A$16.86M$15.85KN/A10
QCLS
Mymd Pharmaceuticals
0.5579 of 5 stars		$4.02
+7.5%		N/AN/A$16.76MN/AN/A6
PASG
Passage Bio
2.6869 of 5 stars		$5.20
+2.4%		$13.25
+154.8%		-29.5%$16.68MN/AN/A130
TRAW
Traws Pharma
3.2137 of 5 stars		$1.62
+1.9%		$8.00
+393.8%		+13.7%$16.45M$2.79MN/A17

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:REVB) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel